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The effi  cacy of bariatric surgery performed 
in the public sector for obese patients with 
comorbid conditions
Abstract
Objective: To determine the effi  cacy of bariatric surgery in the public sector for 
the treatment of complicated obesity.
Design, setting and participants: A longitudinal observational study of obese 
participants with comorbid conditions, aged 21–73 years, who underwent 
publicly funded bariatric surgery. Data were extracted from clinical databases 
(1 October 2009 to 1 September 2013) and recorded at seven time points. 
Participants are from an ongoing public obesity program.
Main outcome measures: Postoperative weight loss and partial or full resolution 
of: type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidaemia and 
obstructive sleep apnoea (OSA).
Results: The 65 participants in the cohort lost a mean weight of 22.6 kg (SD, 
9.5 kg) by 3 months, 34.2.kg (SD, 20.1 kg) by 12 months and 39.9 kg (SD, 31.4 kg) 
by 24 months (P < 0.001). Body mass index (BMI) decreased from a preoperative 
mean of 48.2 kg/m2 (SD, 9.5 kg/m2) to 35.7 kg/m2 (SD, 7.7 kg/m2) by 24 months 
(P < 0.001). Full resolution of comorbid conditions by 18 months (P < 0.001) 
was achieved by almost half of those with baseline T2DM, nearly two-thirds 
with HTN and three-quarters of those with OSA, with continued improvements 
beyond 24 months.
Conclusions: Bariatric surgery performed in the public sector is effi  cacious in 
the treatment of obese patients with comorbid conditions. Our fi ndings parallel 
similar studies suggesting that there is equal benefi t in publicly funded and 
privately performed procedures. This study highlights that obese patients reliant 
on public health care maintain suffi  cient intrinsic motivation in the absence of 
payment and supposed value-driven incentive. Improved access to bariatric 
surgery in the public sector can justifi ably reduce the health inequities for those 
most in need.
O
besity (body mass index 
[BMI]  30 kg/m2) is a grow-
ing health problem and is 
recognised as one of the largest con-
tributors to the chronic burden of dis-
ease. Currently, 28% of Australians 
are obese, placing our nation second 
for men and fi fth for women among 
OECD (Organisation for Economic 
Co-operation and Development) coun-
tries ranked by prevalence of obesity.1,2 
In Australia, an inverse relationship 
exists between high obesity preva-
lence and low socioeconomic status; 
incidence is almost double for areas 
indexed as the most disadvantaged 
compared with areas within the high-
est strata.3 Those living more remotely 
also have higher obesity rates — 59% 
versus 32%.2 Among Indigenous 
Australians, the prevalence of obe-
sity is almost double (34% versus 18%) 
and that of type 2 diabetes mellitus 
(T2DM) is triple that of non-Indig-
enous adults, resulting in sevenfold 
greater mortality due to diabetes.2,4
Bariatric surgery is an effec-
tive treatment of severe obesity 
(class III [BMI  40 kg/m2] or class 
II [BMI  35 kg/m2] with comorbid 
conditions) and is purportedly cost-
effective, compared with conservative 
measures.5-7 The evidence supports 
sustained postoperative weight loss, 
ameliorating obesity-related comor-
bid conditions. The Swedish Obesity 
Study showed a marked reduction in 
hypertriglyceridaemia, T2DM and hy-
peruricaemia with surgery after 2 and 
10 years.6 The resultant postsurgical 
weight loss substantially reduces, re-
solves and even prevents the metabolic 
complications associated with increas-
ing central adiposity, with 73%–95% 
T2DM remission rates by 2 years, de-
pending on the type of surgery.8,9
The heavy economic burden of 
obesity and its comorbid conditions 
may be alleviated in the long term by 
surgical management, despite upfront 
resource costs.10 Severely obese indi-
viduals incur twofold higher mean an-
nual health care costs ($2788 v $1472) 
and use double the number of medica-
tions annually (11.4 v 5.3 per person) 
compared with the general popula-
tion.7,11 Weight loss surgery can reduce 
the number of medications required 
and lower individual health care costs 
by 26%, a direct saving of $506 per 
person.7,12 With evidence of reduced 
mortality and an acceptably low 
complication profi le (estimated mean 
30-day mortality < 0.3%), bariatric pro-
cedures are supported by national and 
international health bodies.13-15
The National Health and Medical 
Research Council (NHMRC) 2013 
guidelines recommend bariatric 
surgery as the most benefi cial and 
cost-effective management for mo-
tivated individuals with severe obe-
sity.16 Motivation is an essential factor 
in considering whether an individual 
with obesity and comorbid condi-
tions is a suitable candidate for sur-
gery. Surgery is not the fi nal step in 
the clinical pathway of severe obesity 
management; postoperative commit-
ment to lifestyle change and regular 
follow-up are requisite for successful 
weight loss and continued improve-
ment in health.16 Most individuals are 
motivated to have surgery for greater 
control of medical ailments, yet it is 
unknown whether this applies to those 
whose procedure is fully funded.17
Since 1992, Medicare has re-
imbursed the cost of bariatric surgery 
in the private sector. As most surgery 
is carried out in private hospitals with 
large out-of-pocket expenses for those 
without private health insurance, a 
signifi cant inequity in obesity man-
agement exists.18 Paradoxically, this 
surgery is least accessible to those who 
are likely to be in greatest need. Since 
October 2009, a pilot program has been 
underway in the Sydney and South 
Western Sydney Local Health Districts 
in which bariatric surgery has been 
publicly funded for a limited number 
of patients meeting strict inclusion cri-
teria. There are no Australian studies 
to date that have identifi ed if publicly 
funded surgical intervention for se-
vere obesity confers the same health Editorial p 184
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benefi ts seen in private health care. 
This study aims to assess the effi cacy 
of bariatric surgery for such patients in 
the Australian public health system.
Methods
Study design
Sixty-eight moderately to severely 
obese participants with comorbid 
conditions were deemed eligible for 
bariatric surgery, and inclusion in 
our study. Participants were attend-
ees at an ongoing collaborative pilot 
program run by one of three obesity 
clinics based within the Sydney and 
South Western Sydney Local Health 
Districts. All participants received 
conservative management for their 
obesity and related health condi-
tions delivered by a multidisciplinary 
team trained in obesity management. 
Participants were seen 6- to 12-weekly 
for dietary advice, behavioural modifi -
cation, advice on physical activity and, 
where appropriate, very low energy 
diets (VLEDs) and pharmacotherapy. 
Participants with substantial obesity-
related comorbid conditions who had 
not achieved adequate weight reduc-
tion with conservative intervention, 
and who were interested in surgical 
management, were assessed by their 
multidisciplinary team to deter-
mine suitability for bariatric surgery. 
Longitudinal data were collected on 
those individuals who underwent 
bariatric surgery for management of 
resistant obesity and associated co-
morbid conditions.
The inclusion criteria for bariatric 
surgery were: age 18–75 years, mini-
mum class II obesity (BMI  35 kg/m2) 
with comorbid conditions, completion 
of at least 1 year of medical interven-
tion during which the participant had 
demonstrated commitment to lifestyle 
change, and surgery before 31 May 
2013 (enabling a minimum follow-up 
period of 3 months). Exclusion criteria 
were: inability to consent, irreversible 
endocrine causes of obesity and sig-
nifi cant comorbid conditions that were 
expected to result in poor outcomes 
from surgery, such as unstable car-
diovascular disease and uncontrolled 
psychiatric illness. Participants un-
derwent 2 weeks of VLED before the 
surgery to reduce abdominal adiposity 
and liver volume in particular, as liver 
size can complicate surgical access.19 
They were also instructed about the 
necessary commitment to postopera-
tive care, specifi cally the importance 
of nutritional input. Two of us (C J T 
and D J M) performed either laparo-
scopic sleeve gastrectomy (LSG) or 
laparoscopic adjustable gastric band-
ing (LAGB) at a single public hospital. 
The type of surgery performed was de-
cided by the participant in conjunction 
with the surgeon, after being briefed 
on the techniques, risks and expected 
benefi ts of each procedure. All par-
ticipants were screened for nutritional 
defi ciencies before and after surgery.
Ethics approval was obtained 
from four Human Research Ethics 
Committees within the Sydney and 
South Western Sydney Local Health 
Districts. All participants gave writ-
ten consent for use of their records for 
research purposes.
Clincial and biochemical 
assessments
Surgeries were performed on an as-
needed basis from 1 October 2009 to 
31 May 2013. Pre- and postoperative 
results were analysed at seven time 
points until 1 September 2013. The 
baseline (preoperative) measurements 
were recorded at the start of the 
VLED, at least 2 weeks before sur-
gery (time zero). Postoperative data 
were recorded from follow-up ap-
pointments at 3, 6, 12, 18, 24 and 
36 months. The primary end points 
analysed were weight, BMI and 
waist circumference, and second-
ary end points were four common 
obesity-related comorbid conditions: 
T2DM, dyslipidaemia, hypertension 
(HTN), and obstructive sleep apnoea 
(OSA). Improvement was defi ned by 
normalisation of laboratory markers 
(T2DM and dyslipidaemia), blood 
pressure sphygmomano metry (HTN) 
and polysomnography results (OSA). 
Comorbid conditions were consid-
ered “partially resolved” when par-
ticipants’ measurements fell within 
normal limits, the number of medi-
cations was reduced or the use of the 
continuous positive airway pressure 
(CPAP) device was discontinued. 
Comorbid conditions were deemed 
“fully resolved” when normal meas-
urements remained after all relevant 
medications were discontinued.
Defi nition of comorbid conditions
T2DM was defi ned as fasting blood 
glucose levels  7 mmol/L, glycated 
haemoglobin level  6.5% and/or re-
quirement of at least one oral hypo-
glycaemic agent. HTN was defi ned as 
systolic blood pressure  140 mmHg, 
diastolic blood pressure  90 mmHg 
and/or requirement of at least one 
anti hypertensive agent. Dyslipidaemia 
was defi ned as total cholesterol level 
 5.0 mmol/L, low-density lipopro-
tein level  3.5 mmol/L, triglyceride 
level  2.0 mmol/L, or high-density 
lipoprotein level  1.01 mmol/L for 
men and  1.3 mmol/L for women, 
and/or requirement of at least one 

















N (n) 65 (65) 65 (65) 55 (58) 49 (52) 30 (33) 17 (23) 7 (10)
BMI (SD), kg/m2 48.2 (9.5) 40.8 (8.3)* 38.9 (7.9)* 36.2 (7.7)* 38.2 (12.1)* 35.7 (7.7)* 38.7 (9.4)†
Weight (SD), kg 136.5 (30.3) 113.9 (25.2)* 108.3 (24.8)* 101.1 (22.4)* 99.3 (20.8)* 97.6 (21.9)* 108.6 (25.6)†
Waist circumference 
(SD), cm
132.2 (16.5) 117.7 (15.2)* 114.9 (14.7)* 109.4 (13.7)* 110.2 (12.3)* 108.4 (15.8)* 114.9 (14.6)*
% weight loss from 
baseline
0 17% 21% 26% 27% 29% 21%
BMI = body mass index. N = total number of participants who attended follow-up. n = total number of participants including those lost to follow-up. 
* Comparison between baseline and follow-up; P < 0.001. † Comparison between baseline and follow-up; P < 0.05. 
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lipid-lowering medication.20,21 OSA 
was defi ned according to symptoms 
(snoring, observed apnoea, daytime 
somnolence), treated HTN and the ap-
noea–hypopnoea index record from 
polysomnography.
Statistical analysis
The results at the seven time points 
were reported as mean and SD. The 
differences were tested for signifi cance 
using paired t tests for continuous 
variables and the McNemar test for 
paired categorical variables. The t test 
was used to evaluate between-surgery 
differences in mean weight at baseline 
and subsequent time points, to assess 
the validity of combining the two sur-
gery types in analyses. Mixed-model 
regression was used to determine if 
signifi cant change in weight occurred 
over time at all seven time points, to 
account for reductions in sample size 
with time. All statistical analysis was 




Of the 68 participants offered sur-
gery, two declined and one moved 
interstate. Sixty-fi ve participants (41 
women and 24 men) with a mean age 
of 51.5 years (SD, 11.8 years; range, 
21–73 years) underwent bariatric 
surgery between 1 October 2009 and 
31 May 2013. The level of comorbid 
conditions in the group at baseline 
was high, with a mean of eight condi-
tions per patient and class III (severe) 
obesity. From baseline to 18 months, 
only three participants were lost to 
follow-up at each time point; however, 
numbers are lower with time as op-
erations were done at different times 
(ie, only 10 patients had surgery 36 
months ago whereas 65 had surgery 3 
months ago, 58 had surgery 6 months 
ago, etc [see Box 1]). Data on all par-
ticipants who completed follow-up at 
each respective time point according 
to surgery date are presented in Box 1 
and Box 2.
Intraoperative outcomes
All 65 surgeries were performed 
laparoscopically and none required 
conversion to open surgery. The most 
commonly performed procedure was 
LSG (57 patients; versus eight patients 
who had LAGB). Despite it appearing 
that greater weight change occurred 
in the LSG group, the difference was 
not signifi cant at 3 months (P = 0.58), 
12 months (P = 0.25) or 24 months 
(P = 0.17). There were no signifi cant 
intraoperative complications (one 
participant had a haematoma that 
resolved with immediate evacuation) 
and length of hospital stay was within 
expected times for all patients (LSG, 
three nights; LAGB, one night).
Short-term postsurgical outcomes 
(3–6 months)
There was a reduction in all primary 
end points in the early postoperative 
period. By 3 months there was a mean 
weight reduction of 22.6 kg (SD, 9.5 kg) 
(Box 3) with a 7.4 kg/m2 mean reduc-
tion in BMI and 14.5 cm mean reduc-
tion in waist circumference (Box 1). All 
comorbid conditions showed partial 
resolution from 3 months (Box 2). Of 
the numbers of participants who had 
each comorbid condition at baseline 
and who had data available, there was 
full resolution by 6 months in 20/45 
with T2DM, 14/43 with HTN, 7/47 
with dyslipidaemia and 17/41 with 
OSA (Box 2). The requirement for all 




By 1 year, there was a signifi cant re-
duction in all anthropometric meas-
ures. The mean weight loss was 34.2 kg 
(SD, 20.1 kg), and the mean BMI was 
reduced by 12 kg/m2 to 36.2 kg/m2 (SD, 
7.7 kg/m2). By 18 months, of those who 
reported the respective comorbid con-
ditions at baseline, almost half of the 
group had full remission of T2DM 
and three-quarters had resolution of 
OSA. Modest resolution of dyslipid-
aemia was seen with both a signifi cant 
rise in high-density lipoprotein and 
reduction in triglycerides occurring 
transiently at 6–12 months in 7 of 47 
patients who had dyslipidaemia at 
baseline (P < 0.001).
Long-term postsurgical outcomes 
(24–36 months)
The trend for continued weight loss 
and partial or full resolution of co-
morbid conditions appears maximal 
at 12–24 months. While the smaller 
group sizes at the 24- and 36-month 
follow-ups provided less power for 
statistical analysis, primary and sec-
ondary end points remained stable 
(P < 0.001). The maximal amount 
of mean weight loss occurred at 24 
months (39.9 kg; SD, 31.4 kg). Three-
quarters of the cohort had reduced 
the number of medications taken for 
HTN and T2DM by 18–24 months, 
and by 36 months, all had reduced the 
number of antihypertensive medica-
tions (Box 4).
Postoperative complications
Transient nutritional deficiencies 
were found in three of 65 partici-
pants, improving within 3 months 
with replacement treatment. Of the 
eight patients who had LAGB, one 
underwent conversion, due to gastric 
2  Proportions of patients* who continued to have conditions found at baseline
Comorbid 
condition














T2DM 53 36/52† 25/45† 21/42† 12/23† 8/17‡ 3/6
HTN 51 45/51‡ 29/43† 18/40† 10/27† 4/12‡ 2/6‡
Dyslipidaemia 58 45/58‡ 40/47 33/42 13/24‡ 8/15‡ 4/6
OSA 41 37/41 24/41‡ 15/41† 6/24† 4/17‡ 2/5
OSA requiring CPAP 27 18/27 14/23‡ 8/22† 4/13‡ 2/8‡ 1/3
CPAP = continuous positive airway pressure. HTN = hypertension. OSA = obstructive sleep apnoea. T2DM = type 2 diabetes mellitus. * Numerators are 
number of participants who had that condition at that time point. Denominators are total number of participants who had that condition at baseline and 
had data at that time point. † Comparison between baseline and follow-up; P < 0.001. ‡ Comparison between baseline and follow-up; P < 0.05.  
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band erosion, to a Roux-en-Y bypass 
at 18 months. Of the participants 
who had LSG, one had a small bowel 
obstruction secondary to adhesions 
and required laparoscopic division at 
2 years. Three participants required 
endoscopic stomach dilatation and a 
further three continued to experience 
nausea, dyspepsia and/or vomiting 
at 3 months, but this resolved by 6 
months for two and at 12 months for 
one participant.
Weight change over time
A total of 288 observations for weight 
from 65 participants were avail-
able for linear mixed-model analysis. 
Signifi cant change in mean weight was 
observed over time (P < 0.001). Mean 
weight adjusted for baseline weight 
decreased from 136.5 kg at baseline 
to 101.1 kg at 12 months. Stratifying 
the analysis by sex showed that men 
had a higher mean baseline weight, 
147.5 kg (SD, 36.9 kg) compared with 
women, 130.1 kg (SD, 23.8 kg), but no 
difference was observed after 1 year 
(Box 3).
Discussion
In our study, the signifi cant weight lost 
by obese participants who underwent 
bariatric surgery occurred early and 
was sustained over the fi rst 3 years. 
The mean maximal weight loss was 
almost one-third of participants’ pre-
operative weight and was achieved by 
24 months. Despite decreasing sample 
sizes, our results showed sustained 
weight loss at 36 months.
There was full or partial resolution 
of all comorbid conditions tested, 
except dyslipidaemia, in most par-
ticipants by 2 years. Different rates 
of resolution of comorbid conditions 
occurred, with remission of T2DM 
being the earliest. By 24 months, 
there was an associated resolution of 
T2DM, HTN and OSA, or the need 
for pharmacotherapy or devices was 
reduced in most patients, yet dyslipi-
daemia showed inconclusive results. 
These fi ndings parallel other bariat-
ric studies.22,23 The Swedish Obesity 
Study found isolated improvements in 
hyper triglyceridaemia postoperatively 
(including after LAGB), although the 
most consistent improvements in lipid 
profi les have been seen after Roux-
en-Y bypass surgery.6,24
Most LAGB procedures were per-
formed in the fi rst year of the study, 
until LSG became a preferred option 
due to its greater weight loss profi le 
with minimal additional complica-
tions and the lower need for surgical 
follow-up. However, throughout the 
study, participants had autonomy of 
procedure choice (on surgeon recom-
mendation). While this may suggest 
an avenue for bias (the participants 
chose their “intervention”), bariatric 
surgery is an elective procedure, and it 
was deemed necessary to replicate the 
protocol in the private sector. The limi-
tations of our study include its small 
size, that it is a case series, that it is 
non-blinded, possible bias due to par-
ticipants choosing their surgery type, 
and the use of a clinical database with 
the possibility of missing or inaccurate 
values imputed by health profession-
als. The low adverse events observed 
in our study are consistent with those 
reported in the literature.
The direct operative costs of per-
forming these surgeries in the public 
sector in our study were estimated to 
be $7000–$9000 (LSG incurred greater 
up-front theatre costs than LAGB). 
Perioperative costs, including 2 years 
of postsurgical visits, may approach 
$2000 per person, taking the total 
cost to $9000–$11 000 per person. A 
2005 paper reported the annual cost 
of managing an individual with T2DM 
as $9095–$15 850.25 Thus, if an obese 
person with T2DM has bariatric sur-
gery, the operation would pay for itself 
after about 1 year.
The participants’ baseline charac-
teristics are representative of a typical 















* Weight change at all seven time points is signifi cant (P < 0.001). Despite diff erences in weight lost 
for men and women, there were no signifi cant between-sex diff erences. 
4  Number of patients with a reduction in medications used at each time point after bariatric surgery



















 reduced use of 
medication
3 65 31 60 28 64 6
6 54 34 54 29 53 10
12 48 37 47 25 44 12
18 29 22 23 17 24 12
24 16 12 16 15 13 3
36 6 6 6 4 4 1
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demographic seen in the public sector, 
supporting extrapolation of our results 
to a wider population. The high at-
tendance rate at 2 years shows that the 
cohort demonstrated adequate motiva-
tion to justify surgical intervention. 
The health potential from bariatric 
surgery ranges from improved qual-
ity of life and amelioration of comorbid 
conditions to full resolution of compli-
cations and reduced mortality for all 
individuals, paying or not. Strategies 
to prioritise access are therefore rec-
ommended to reduce the apparent 
inequality that exists. Limited access 
to surgery discriminates against those 
who cannot afford the out-of-pocket 
costs, yet it is likely that this subgroup 
would benefi t most. In conclusion, we 
hope that our study provides an evi-
dence base for the surgical treatment 
of obesity in the public health system 
and, in turn, that consideration will 
be given to increasing the supply of 
publicly funded bariatric surgery in 
Australia.
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